BETA
Your AI-Trained Oncology Knowledge Connection!
Stay up to date on practice-changing data in community practice.
Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL
Pirtobrutinib shows significant improvements in patient-reported outcomes for relapsed CLL/SLL, outperforming standard therapies in a recent trial.
Read More
Understanding the Role of Zanubrutinib for the Treatment of CLL
Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.
Listen
Exploring BTK Inhibitors for Patients With CLL and Del(17p) Mutations
During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.
Exciting Activity in Chronic Lymphocytic Leukemia
In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.
FDA Approves Zanubrutinib Tablet for All Indications
The FDA has approved a tablet version of zanubrutinib for all indications, improving convenience and reducing pill burden for patients with blood cancers.
Tagraxofusp Yields Deep Responses as Frontline BPDCN Therapy
During a live event, Gary J. Schiller, MD, explored the outcomes of the phase 1/2 trial of tagraxofusp-erzs in patients with blastic plasmacytoid dendritic cell neoplasm.
